We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Nevro (NVRO) in Your Portfolio
Read MoreHide Full Article
Nevro Corp. (NVRO - Free Report) is well-poised for growth, backed by strong international presence, solid prospects in the Spinal Cord Stimulation (SCS) market and commitment toward innovation. However, intense competition remains a concern.
The stock currently carries a Zacks Rank #3 (Hold).
Price Performance
Shares of Nevro have surged 31.9%, against the industry’s decline of 3.2% in a year’s time. Further, the S&P 500 Index dipped 0.2%.
What’s Weighing on the Stock?
Intense competition in the SCS market remains a woe. Per management, the primary competitive factors are company brand recognition, clinical research leadership, pricing and reimbursement et al.
Factors to Bolster Nevro
Nevro continues to benefit from sturdy international foothold, thereby driving the company’s overall performance. Per management, growth in Europe is anticipated to improve worldwide revenues in 2019.
Further, robust prospects in the SCS market have been favoring the company over a considerable period of time. Aging demographics, high cost related to therapy, strict regulatory approvals and an excessive reliance on the traditional SCS therapy are the major factors impacting the global SCS market.
Per a Market Data Forecast report, the global SCS market is estimated to reach $2,827.4 million at a CAGR of 8.6% (between 2018 and 2023).
Consistent focus on innovation has been crucial in bolstering the company’s overall performance.
A strong outlook for 2019 instills optimism in the stock. Notably, the company expects worldwide revenues between $368 million and $374 million. Moreover, gross margins are expected in the high 60% of revenues.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $374.2 million, indicating a decline of 3.4% from the year-ago reported figure. For adjusted loss per share, the same stands at $3.87.
Baxter has a long-term earnings growth rate of 12.8%.
Amedisys has a long-term earnings growth rate of 16.3%.
HMS Holdings has a long-term earnings growth rate 11%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Here's Why You Should Retain Nevro (NVRO) in Your Portfolio
Nevro Corp. (NVRO - Free Report) is well-poised for growth, backed by strong international presence, solid prospects in the Spinal Cord Stimulation (SCS) market and commitment toward innovation. However, intense competition remains a concern.
The stock currently carries a Zacks Rank #3 (Hold).
Price Performance
Shares of Nevro have surged 31.9%, against the industry’s decline of 3.2% in a year’s time. Further, the S&P 500 Index dipped 0.2%.
What’s Weighing on the Stock?
Intense competition in the SCS market remains a woe. Per management, the primary competitive factors are company brand recognition, clinical research leadership, pricing and reimbursement et al.
Factors to Bolster Nevro
Nevro continues to benefit from sturdy international foothold, thereby driving the company’s overall performance. Per management, growth in Europe is anticipated to improve worldwide revenues in 2019.
Further, robust prospects in the SCS market have been favoring the company over a considerable period of time. Aging demographics, high cost related to therapy, strict regulatory approvals and an excessive reliance on the traditional SCS therapy are the major factors impacting the global SCS market.
Per a Market Data Forecast report, the global SCS market is estimated to reach $2,827.4 million at a CAGR of 8.6% (between 2018 and 2023).
Consistent focus on innovation has been crucial in bolstering the company’s overall performance.
A strong outlook for 2019 instills optimism in the stock. Notably, the company expects worldwide revenues between $368 million and $374 million. Moreover, gross margins are expected in the high 60% of revenues.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $374.2 million, indicating a decline of 3.4% from the year-ago reported figure. For adjusted loss per share, the same stands at $3.87.
Key Picks
Some better-ranked stocks from the broader medical space are Baxter International Inc. (BAX - Free Report) , Amedisys, Inc. (AMED - Free Report) and HMS Holdings Corp. , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter has a long-term earnings growth rate of 12.8%.
Amedisys has a long-term earnings growth rate of 16.3%.
HMS Holdings has a long-term earnings growth rate 11%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>